| I N TR ODU C TI ON
amnionless (AMN) and cubilin (CUBN). 2 In humans, mutations in either the AMN or CUBN genes lead to selective Cbl malabsorption known as
Imerslund-Gräsbeck syndrome (IGS). 3, 4 In dogs, selective intestinal Cbl malabsorption, comparable to IGS in humans, has been described in Australian Shepherds, 5, 6 Beagles, [7] [8] [9] [10] [11] [12] Border Collies, [13] [14] [15] [16] and Giant Schnauzers. 17 It is an autosomal recessive trait caused by 2 distinct AMN mutations in Giant Schnauzers 17 and Australian Shepherds. 5 Our group and others recently identified 2 independent CUBN mutations in Border Collies 18, 19 and Beagles. 10, 20 Although the disease is rare, substantial carrier frequency has been noted in affected breeds 20 and thus disease occurrence is more common regionally. 8 Clinical signs of IGS usually occur in the juvenile period as fetal Cbl stores gradually diminish.
Typical clinical signs include failure to thrive, anorexia, and lethargy. Similar to infants, dogs may also be presented with more subtle clinical signs such as intermittent pyrexia, glossitis, aphthous stomatitis, and paresthesia. 12, 15 Laboratory abnormalities consist of neutropenia, mild to moderate normocytic anemia, hyperammonemia, increased liver enzyme activities, and mild proteinuria. [8] [9] [10] [11] [12] [13] [14] [15] [16] Left untreated, IGS is life-threatening as a result of metabolic derangements and immunodeficiency. [9] [10] [11] 16 Treatment consists of parenteral Cbl supplementation, which leads to rapid and complete clinical remission when administered sufficiently early in the course of disease, and the long-term prognosis is excellent with adequate lifelong treatment. 6, [8] [9] [10] 12 In humans with IGS, clinical signs and biochemical variables such as MMA are monitored and usually normalize when treatment is adequate. [21] [22] [23] In dogs with IGS, long-term monitoring (including regular assessment of markers of cellular Cbl availability) has not been carried out. The amount and frequency of administration of CN-Cbl in the initial replenishment period differed considerably and was 100 mg q7d (n 5 2), 1500 mg q7d (n 5 1), or 1000 mg, q4wk (n 5 1) before the first urine sample (t0) was collected. All six dogs were considered to be free of clinical signs by their owners and the primary care veterinarians at the time of the baseline urine evaluation. shipped on dry ice and by a commercial carrier (n 5 3) or brought to our clinic by the owner (n 5 3).
| Healthy control dogs
Urinary MMA concentrations were determined in 28 clinically healthy dogs that belonged to staff or students and had normal routine labora- Urine and serum MMA concentrations were analyzed at the Division of Clinical Chemistry of the University Children's Hospital Zurich according to accredited methods. 26 In brief, samples were supplemented with an internal standard, precipitated, and analysis was done by gas-liquid chromatography-tandem mass spectrometry (GC-MS) on an Ultimate 3000 XRS UHPLC system (Dionex, Thermo Scientific, Waltham, MA) with a SCIEX5500 mass spectrometer (SCIEX, Framingham, MA) using multiple reaction monitoring. The lower limit of quantification for this method was 25 nmol/L in serum and 651 nmol/L in urine. Results for urine MMA were expressed as mmol MMA per mol creatinine. Creatinine concentrations were determined using a kinetic Jaffe method on a DxC600 clinical chemistry analyzer (Beckman Coulter International S.A. Nyon, Switzerland) using commercial reagents. The interassay CVs of the analyses were 5.8%
for MMA in serum and urine and 2.7% for creatinine in urine. 
| Statistical analysis

| Serum Cbl concentrations
| Urinary MMA concentrations
Thirty-one urinary MMA results were available in 5 dogs, which were on a bimonthly Cbl supplementation schedule, over a median of 6 (range, 3-10) months. Results ranged from 1.6 to 10.5 (median, 4.9) mmol/mol creatinine in 4 dogs, whereas higher urinary MMA concentrations (45.7 to 50 mmol/mol creatinine) were detected in dog 4 (Figure 1, red squares) . Urinary MMA concentrations did not differ between bimonthly and monthly Cbl supplementation (P 5 .58).
| Additional measurement of serum MMA concentrations in dog 4
In dog 4, additional serum samples were available at the time of the 2nd and 3rd bimonthly OH-Cbl injections, and analysis of serum MMA concentrations detected 657 and 591 nmol/L, respectively (range in healthy dogs, 539-1140 nmol/L).
| D ISC USSION
Our findings provide evidence that the schedule for administration of parenteral OH-Cbl can be adjusted to include longer intervals between dosing in Beagles with IGS provided that patients are regularly monitored. Intervals of up to 2 months between IM injections of 1 mg OH-Cbl appear reasonable and therefore can be recommended.
All dogs with IGS were deemed clinically normal by the primary care veterinarians and owners throughout the Cbl supplementation period.
A similar approach is used in human medicine wherein the frequency of Cbl injections relies primarily on the health status of the patient, and thus the interval between injections can be increased for maintenance treatment in infants with various inborn errors of cellular Cbl metabolism. 4, 23, 27, 28 Monthly IM injections of 1 mg OH-Cbl constitute the most common maintenance regime in children with IGS. 38 We chose to determine MMA in urine rather than in serum or plasma because collection of voided urine samples is less invasive and more convenient for dog owners. In addition, we were concerned that owner compliance would suffer if consecutive blood sampling was required, especially when all dogs were free of clinical signs throughout the study period.
There are currently no guidelines with regard to urinary MMA cutoff points for IGS in humans, and positive responses to Cbl supplementation have been defined only for infants with defects of the mitochondrial enzyme, methylmalonyl-CoA mutase. 38 Very little is known about biochemical responses to Cbl supplementation in dogs with IGS.
Although it is well known that urinary MMA concentrations at the time of diagnosis in untreated ill dogs are usually in the thousands, 6, 7, 9, 10, 13, 14, 17, 24, 25 responses to Cbl supplementation using urinary MMA as a marker of cellular Cbl availability have only been documented in 2 Border collies, 13,14 2 Beagles, 7,9 and 1 family of Giant Schnauzers. 17, 24 Normal urinary MMA concentrations were noted with weekly 9 or biweekly 7 IM injection of various doses of Cbl as well as with parenteral administration of 1 mg Cbl every 1-2 months. 13 The use of urinary MMA for monitoring the biochemical response to treatment of IGS was described in more detail in a family of Giant Schnauzer puppies. 17 A single IM injection of 1 mg CN-Cbl was found to be sufficient for preventing relapse of clinical and laboratory abnormalities for 2 months despite persistently subnormal serum Cbl concentrations. The same puppies also had urinary MMA concentrations measured using GC-MS, and urine MMA ranged from 14 to 113 mmol/mol creatinine during the 2 months post-treatment. Agematched control dogs excreted < 34 mmol/mol creatinine. 17 The affected puppies remained healthy and grew to normal size with regular monthly IM injections of 1 mg CN-Cbl, although this was not monitored long term with MMA measurements. and its saturation index. 48 Holotranscobalamin is the biologically active Cbl fraction that can be delivered to all DNA-synthesizing cells, and its measurement appears to better reflect recent Cbl absorption in humans. 49 However, these assays currently are not available for dogs.
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